Compare iShares MSCI France ETF (EWQ) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Novavax Inc — how do they compare? iShares MSCI France ETF trades at $45.25, while Novavax Inc trades at $8.23 (market cap $1.39B). The key difference: iShares MSCI France ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| EWQ | NVAX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $11.19 |
52-Week Low | $41.43 | $6.22 |
Market Cap | — | $1.39B |
Enterprise Value | — | $890.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $8.21, down 2.49% amid bearish technical signals and negative cash flow trends. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 and three consecutive earnings beats, but faces profitability challenges with negative net income margin and ROE. Recent news highlights shareholder dissent and underperformance versus broader market trends, while analyst consensus remains bullish with a $14 price target representing 70% upside potential.
The outlook balances significant upside potential against substantial execution risks. Positive catalysts include consistent earnings beats and strong analyst support, but concerns persist around cash burn, negative equity, and competitive vaccine market pressures. Investors face volatility from operational challenges despite attractive valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
